DK2235007T3 - Ikke-steroide mineralocorticoid-receptorantagonister af 6h-dibenz0 [b,e] oxepin - Google Patents

Ikke-steroide mineralocorticoid-receptorantagonister af 6h-dibenz0 [b,e] oxepin

Info

Publication number
DK2235007T3
DK2235007T3 DK08866835.5T DK08866835T DK2235007T3 DK 2235007 T3 DK2235007 T3 DK 2235007T3 DK 08866835 T DK08866835 T DK 08866835T DK 2235007 T3 DK2235007 T3 DK 2235007T3
Authority
DK
Denmark
Prior art keywords
oxepin
dibenzo
steroid
receptor antagonists
mineralocorticoid receptor
Prior art date
Application number
DK08866835.5T
Other languages
English (en)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2235007(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2235007T3 publication Critical patent/DK2235007T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK08866835.5T 2007-12-19 2008-12-09 Ikke-steroide mineralocorticoid-receptorantagonister af 6h-dibenz0 [b,e] oxepin DK2235007T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
DK2235007T3 true DK2235007T3 (da) 2012-12-17

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08866835.5T DK2235007T3 (da) 2007-12-19 2008-12-09 Ikke-steroide mineralocorticoid-receptorantagonister af 6h-dibenz0 [b,e] oxepin

Country Status (33)

Country Link
US (1) US7994164B2 (da)
EP (2) EP2235007B1 (da)
JP (1) JP5562866B2 (da)
KR (1) KR101254382B1 (da)
CN (1) CN101903377B (da)
AR (1) AR069554A1 (da)
AU (1) AU2008343524B2 (da)
BR (1) BRPI0820805A2 (da)
CA (1) CA2710409C (da)
CL (1) CL2008003600A1 (da)
CO (1) CO6300953A2 (da)
DK (1) DK2235007T3 (da)
DO (1) DOP2010000185A (da)
EA (1) EA017668B1 (da)
EC (2) ECSP10010266A (da)
ES (2) ES2459318T3 (da)
GT (1) GT201000179A (da)
HR (1) HRP20120916T1 (da)
IL (1) IL206353A (da)
MA (1) MA31910B1 (da)
MX (1) MX2010006911A (da)
MY (1) MY150474A (da)
NZ (1) NZ586300A (da)
PE (1) PE20091057A1 (da)
PL (1) PL2235007T3 (da)
PT (1) PT2235007E (da)
RS (1) RS52594B (da)
SI (1) SI2235007T1 (da)
TN (1) TN2010000292A1 (da)
TW (1) TWI431010B (da)
UA (1) UA100131C2 (da)
WO (1) WO2009085584A1 (da)
ZA (1) ZA201004257B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
MX2010006313A (es) 2007-12-19 2010-06-25 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
BRPI1009257A2 (pt) * 2009-03-12 2016-03-08 Lilly Co Eli antagonista receptor de mineralocorticoide e métodos de uso.
ES2641144T3 (es) 2010-05-10 2017-11-07 Inserm (Institut National De La Santé Et De La Recherche Medicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
JP6263606B2 (ja) 2013-05-02 2018-01-17 ファイザー・インク Pde10阻害剤としてのイミダゾ−トリアジン誘導体
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
ES2707726T3 (es) 2014-06-30 2019-04-04 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides
US20170246166A1 (en) * 2014-11-21 2017-08-31 Eli Lilly And Company 1,2-benzothiazole compounds for the treatment of kidney disorders
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
US20190262363A1 (en) 2016-07-26 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CU24569B1 (es) * 2016-09-24 2022-01-13 Kbp Biosciences Co Ltd Composición farmacéutica como antagonista del receptor de mineralocorticoides
US20230151425A1 (en) 2020-03-11 2023-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
DE3730258A1 (de) * 1986-09-10 1988-04-07 Canon Kk Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
CA2361734A1 (en) 1999-01-26 2000-10-12 Andre Rosowsky Pharmaceutically active compounds and methods of use thereof
CN1911930A (zh) * 2001-11-21 2007-02-14 千禧药品公司 趋化因子受体拮抗剂及其方法和用途
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
AU2004312293A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
WO2005066153A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2006015259A2 (en) 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
AU2005304560C1 (en) 2004-11-10 2013-05-09 Incyte Holdings Corporation Lactam compounds and their use as pharmaceuticals
GEP20115239B (en) 2006-10-31 2011-06-10 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptor antagonists
WO2008119918A1 (en) 2007-03-29 2008-10-09 N.V. Organon Mineralocorticoid receptor antagonists
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
US20100292233A1 (en) 2008-01-25 2010-11-18 Arena Pharmaceuticals, Inc. Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists
BRPI1009257A2 (pt) 2009-03-12 2016-03-08 Lilly Co Eli antagonista receptor de mineralocorticoide e métodos de uso.

Also Published As

Publication number Publication date
KR101254382B1 (ko) 2013-04-15
DOP2010000185A (es) 2010-09-15
CA2710409C (en) 2012-11-06
ES2459318T3 (es) 2014-05-09
US7994164B2 (en) 2011-08-09
RS52594B (sr) 2013-04-30
HRP20120916T1 (hr) 2012-12-31
TW200930721A (en) 2009-07-16
JP2011507868A (ja) 2011-03-10
SI2235007T1 (sl) 2013-01-31
US20090163472A1 (en) 2009-06-25
PT2235007E (pt) 2013-01-22
TN2010000292A1 (en) 2011-11-11
EA201070762A1 (ru) 2010-12-30
MA31910B1 (fr) 2010-12-01
EP2235007A1 (en) 2010-10-06
CN101903377B (zh) 2014-07-09
BRPI0820805A2 (pt) 2015-06-16
HK1144284A1 (en) 2011-02-11
NZ586300A (en) 2012-06-29
AU2008343524B2 (en) 2012-03-08
GT201000179A (es) 2012-04-16
IL206353A0 (en) 2010-12-30
IL206353A (en) 2014-06-30
TWI431010B (zh) 2014-03-21
AU2008343524A1 (en) 2009-07-09
PL2235007T3 (pl) 2013-03-29
AR069554A1 (es) 2010-02-03
MY150474A (en) 2014-01-30
UA100131C2 (uk) 2012-11-26
ES2396605T3 (es) 2013-02-22
ECSP10010266A (es) 2010-07-30
ZA201004257B (en) 2011-11-30
EA017668B1 (ru) 2013-02-28
CN101903377A (zh) 2010-12-01
CA2710409A1 (en) 2009-07-09
CL2008003600A1 (es) 2010-02-19
JP5562866B2 (ja) 2014-07-30
PE20091057A1 (es) 2009-07-20
EP2537845B1 (en) 2014-03-19
KR20100082866A (ko) 2010-07-20
ECSP12012048A (es) 2012-08-31
WO2009085584A1 (en) 2009-07-09
EP2235007B1 (en) 2012-10-31
MX2010006911A (es) 2010-10-05
CO6300953A2 (es) 2011-07-21
EP2537845A1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
DK2235007T3 (da) Ikke-steroide mineralocorticoid-receptorantagonister af 6h-dibenz0 [b,e] oxepin
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
EP1981902A4 (en) ANTAGONISTS OF NOGO RECEPTORS
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
DK2081951T3 (da) Progesteron-receptorantagonister
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
BRPI0821784A2 (pt) receptor de navegação
EP1978022A4 (en) CHROME COMPOUNDS
DK2129654T3 (da) Antagonister af glucagonreceptoren
EP2214676A4 (en) SUBSTITUTED DIAZEPANES AS ANTAGONISTS OF OREXIN RECEPTORS
DK2009992T3 (da) Il-8 receptor-antagonister
EP2004654A4 (en) Kinase Antagonists
EP2350060A4 (en) Melanocortin receptor AGONISTS
DE602007010456D1 (de) Phenyl-pyrazol-derivate als nicht-steroide glucocorticoid-rezeptorliganden
BRPI0810926A2 (pt) Antagonista de crig
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
CU23857B1 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
BRPI0720078A2 (pt) 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a)
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
DE602007008831D1 (de) Cyclohexyl-sulfonamid-derivate mit h3-rezeptoraktivität
BRPI0820779A2 (pt) Derivados de 4-amino-pirimidina